| CBP74172 | |
| I. Background | |
The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. The PD-1 ligands are found on most cancers, and PD-1:PD-L1/2 interaction inhibits T cell activity and allows cancer cells to escape immune surveillance. diabetes. Human CD137 (4-1BB; TNFRS9) is an inducible costimulatory molecule that activates T cells. CD137-CD137L mediated signaling has been shown to be important for proliferation, effector functions and survival of T cells. CD137 is also expressed in NK and NKT cells. Antibodies targeting CD137 activation in immune cells have demonstrated potent anti-tumor effects in cancer patients. | |
| II. Introduction | |
| Expressed gene: | PD1、41BB |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin+800ug/ml hygromycin+10ug/ml blasticidin |
| Mycoplasma Testing: | Negative |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| III. Representative Data | |
Figure 1. Dose Response of Blocking Antibodies in PD-1/41BB Dual Effector Reporter Cells (C64) With PD-L1 aAPC Cells. | |
化工儀器網